Lurasidone in Therapy of Treatment-resistant Ultra-rapid Cycling Bipolar Disorder: Case Report

Overview

Journal Clin Psychopharmacol Neurosci

Specialty Psychiatry

Date 2021 Jul 23

PMID 34294628

Citations 3

Authors

Marcin Siwek

Aleksandra Gorostowicz

Affiliations

Soon will be listed here.

Abstract

Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. It seems to have a favorable metabolic profile and low risk of causing adverse interactions. Here we present a case of a 25-year old female patient with treatment-resistant ultra-rapid cycling bipolar disorder, obesity, hypothyroidism, and epilepsy. Because of predominant depressive symptoms, occasional occurrence of brief psychotic symptoms and patient's somatic comorbidities, treatment with lurasidone was initiated. Clinical improvement was observed 3 weeks and cessation of ultra-rapid cycling course of the disease 8 weeks after the beginning of lurasidone treatment. The patient's level of functioning improved and body mass significantly decreased, with good tolerance of the pharmacotherapy. Lurasidone seems to be a promising treatment option in patients with treatment-resistant rapid cycling bipolar disorder.

Citing Articles

Psychopharmacology and Biological Studies of Psychosis.

Siwek M, Szewczyk B, Chrobak A Brain Sci. 2023; 13(6).

PMID: 37371334 PMC: 10296303. DOI: 10.3390/brainsci13060854.

Lurasidone Augmentation of Clozapine in Schizophrenia-Retrospective Chart Review.

Siwek M, Chrobak A, Gorostowicz A, Krol P, Dudek D Brain Sci. 2023; 13(3).

PMID: 36979255 PMC: 10046327. DOI: 10.3390/brainsci13030445.

Mild Decrease in Blood Glucose Levels May Predict Efficacy of Antipsychotic Lurasidone.

Nagamine T, Nakamura M Clin Psychopharmacol Neurosci. 2023; 21(1):207-209.

PMID: 36700328 PMC: 9889891. DOI: 10.9758/cpn.2023.21.1.207.

References

Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K . Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2013; 171(2):160-8. DOI: 10.1176/appi.ajp.2013.13070984. View

Ketter T, Sarma K, Silva R, Kroger H, Cucchiaro J, Loebel A . LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY. Depress Anxiety. 2016; 33(5):424-34. PMC: 5069590. DOI: 10.1002/da.22479. View

Yatham L, Kennedy S, Parikh S, Schaffer A, Bond D, Frey B . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018; 20(2):97-170. PMC: 5947163. DOI: 10.1111/bdi.12609. View

Wichniak A, Dudek D, Heitzman J, Kaplon-Cieslicka A, Mamcarz A, Samochowiec J . Metabolic risk reduction in patients with schizophrenia treated with antipsychotics: recommendations of the Polish Psychiatric Association. Psychiatr Pol. 2020; 53(6):1191-1218. DOI: 10.12740/PP/113222. View

McIntyre R, Cucchiaro J, Pikalov A, Kroger H, Loebel A . Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry. 2015; 76(4):398-405. DOI: 10.4088/JCP.14m09410. View

Lee S, Tsang A, Kessler R, Jin R, Sampson N, Andrade L . Rapid-cycling bipolar disorder: cross-national community study. Br J Psychiatry. 2010; 196(3):217-25. PMC: 2830056. DOI: 10.1192/bjp.bp.109.067843. View

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F . Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896):951-62. DOI: 10.1016/S0140-6736(13)60733-3. View

Meyer J, Ng-Mak D, Chuang C, Rajagopalan K, Loebel A . Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records. Ann Gen Psychiatry. 2017; 16:36. PMC: 5646018. DOI: 10.1186/s12991-017-0159-x. View

Fountoulakis K, Kontis D, Gonda X, Yatham L . A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Disord. 2013; 15(2):115-37. DOI: 10.1111/bdi.12045. View

10.

Carvalho A, Dimellis D, Gonda X, Vieta E, Mclntyre R, Fountoulakis K . Rapid cycling in bipolar disorder: a systematic review. J Clin Psychiatry. 2014; 75(6):e578-86. DOI: 10.4088/JCP.13r08905. View

11.

Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R . Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334(1):171-81. DOI: 10.1124/jpet.110.167346. View

12.

Gigante A, Barenboim I, Dias R, Toniolo R, Mendonca T, Miranda-Scippa A . Psychiatric and clinical correlates of rapid cycling bipolar disorder: a cross-sectional study. Braz J Psychiatry. 2016; 38(4):270-274. PMC: 7111346. DOI: 10.1590/1516-4446-2015-1789. View

13.

Valenti M, Pacchiarotti I, Undurraga J, Bonnin C, Popovic D, Goikolea J . Risk factors for rapid cycling in bipolar disorder. Bipolar Disord. 2015; 17(5):549-59. DOI: 10.1111/bdi.12288. View

14.

Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N . Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019; 394(10202):939-951. PMC: 6891890. DOI: 10.1016/S0140-6736(19)31135-3. View

15.

Hajek T, Hahn M, Slaney C, Garnham J, Green J, Ruzickova M . Rapid cycling bipolar disorders in primary and tertiary care treated patients. Bipolar Disord. 2008; 10(4):495-502. PMC: 3544929. DOI: 10.1111/j.1399-5618.2008.00587.x. View

16.

Citrome L, Ketter T, Cucchiaro J, Loebel A . Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2013; 155:20-7. DOI: 10.1016/j.jad.2013.10.040. View

17.

Reynolds G, Dalton C, Watrimez W, Jackson J, Harte M . Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats. Clin Psychopharmacol Neurosci. 2019; 17(2):314-317. PMC: 6478088. DOI: 10.9758/cpn.2019.17.2.314. View

18.

Calabrese J, Pikalov A, Streicher C, Cucchiaro J, Mao Y, Loebel A . Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol. 2017; 27(9):865-876. DOI: 10.1016/j.euroneuro.2017.06.013. View

19.

Loebel A, Citrome L . Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression. BJPsych Bull. 2016; 39(5):237-41. PMC: 4706192. DOI: 10.1192/pb.bp.114.048793. View